for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adicet Bio Inc

ACET.OQ

Latest Trade

7.19USD

Change

0.00(0.00%)

Volume

42,991

Today's Range

7.06

 - 

7.25

52 Week Range

6.25

 - 

21.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.19
Open
7.08
Volume
42,991
3M AVG Volume
3.23
Today's High
7.25
Today's Low
7.06
52 Week High
21.40
52 Week Low
6.25
Shares Out (MIL)
31.84
Market Cap (MIL)
228.95
Forward P/E
-6.48
Dividend (Yield %)
--

Next Event

Adicet Bio Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Latest Developments

More

Adicet Reports Second Quarter 2021 Financial Results And Provides Business Updates

Adicet Bio Posts Q1 Loss Per Share $0.82 Including Items

Adicet Reports Fourth Quarter And Full Year 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adicet Bio Inc

Adicet Bio Inc., formerly resTORbio, Inc., is a biotechnology company. The Company is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and solid tumor and hematological indications.

Industry

Biotechnology & Drugs

Contact Info

200 CLARENDON STREET, FLOOR 6

BOSTON, MA

02116

United States

+1.617.4822333

https://www.adicetbio.com/

Executive Leadership

Chen Schor

President, Chief Executive Officer, Secretary, Director

Nick Harvey

Chief Financial Officer

Carrie Krehlik

Chief Human Resource Officer, Senior Vice President

Francesco Galimi

Senior Vice President, Chief Medical Officer

Don G. Healey

Chief Technology Officer

Key Stats

1.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-9.940

2019

-16.870

2020

-5.010

2021(E)

-1.999
Price To Earnings (TTM)
--
Price To Sales (TTM)
24.69
Price To Book (MRQ)
1.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-35.10
Return on Equity (TTM)
-32.59

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up